We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS (EXIT-COVID19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04493242
Recruitment Status : Completed
First Posted : July 30, 2020
Last Update Posted : January 19, 2023
Sponsor:
Information provided by (Responsible Party):
Direct Biologics, LLC

Brief Summary:
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients with severe COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 ARDS Biological: ExoFlo Other: Intravenous normal saline Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:
This is a Phase II, double-blinded, placebo-controlled, randomized controlled trial that enrolled 102 subjects that were admitted with COVID-19 associated moderate-to-severe ARDS across 6 sites in the United States.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center, double-blinded, placebo-controlled, randomized controlled trial.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-blinded
Primary Purpose: Treatment
Official Title: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial
Actual Study Start Date : September 24, 2020
Actual Primary Completion Date : May 1, 2021
Actual Study Completion Date : May 22, 2021


Arm Intervention/treatment
Placebo Comparator: Placebo
Normal saline 100 mL
Other: Intravenous normal saline
Placebo

Experimental: Experimental Dose 1
Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.
Biological: ExoFlo
Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles

Experimental: Experimental Dose 2
Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.
Biological: ExoFlo
Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles




Primary Outcome Measures :
  1. Evaluation of 60-day mortality rate [ Time Frame: 60 days ]
    To evaluate the 60-day mortality rate for IP 15mL as a treatment for COVID-19 associated moderate to severe ARDS compared to placebo. Reducing the mortality rate for hospitalized patients with COVID-19 associated ARDS is a measure of the treatment effect.


Secondary Outcome Measures :
  1. Overall survival rates [ Time Frame: Days 15, 30, 60 ]
    Reducing the mortality rate for hospitalized patients with COVID-19 associated ARDS is a measure of the treatment effect.

  2. Proportion of discharged patients [ Time Frame: Days 7, 30, 60 ]
    Discharge is an unbiased measure of overall clinical improvement.

  3. Time to discharge [ Time Frame: Number of days from the date of randomization until documented discharge from hospital. ]
    Discharge is an unbiased measure of overall clinical improvement.

  4. Incidence of Treatment Emergent Serious Adverse Events [ Time Frame: 61 days ]
    Safety comparison between IP 15 mL and placebo arms

  5. Ventilation free days [ Time Frame: Within 60 days of follow-up ]
    Number of days for which patients are not on mechanical ventilation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy).
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18-85.
  4. COVID-19 positive as defined by positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) SARS-CoV-2.
  5. Moderate to severe ARDS as defined by modified Berlin definition, * which includes timing within 1 week of known clinical insult or new or worsening respiratory symptoms; bilateral opacities not fully explained by effusions, or lung collapse; respiratory failure not fully explained by cardiac failure or fluid overload; PaO2/FiO2 ≤ 200 mm Hg.

    *Modified Berlin definition used in this study is the full Berlin definition, albeit without the PEEP specification, which implies mechanical ventilation.

  6. Hypoxia requiring noninvasive oxygen support such as Nasal Cannula (NC), Nonrebreather (NRB), Bilevel Positive Airway Pressure (BIPAP), Continuous Positive Airway Pressure (CPAP), high flow nasal cannula oxygen (HFNC O2) or mechanical ventilation (MV) despite initiating standard of care.
  7. If the candidate is either a male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. The required duration of usage of double barrier method OR maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.

Exclusion Criteria:

  1. Vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent.
  2. Active malignancy requiring treatment within the last five years.
  3. Major physical trauma in the last 5 days, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries.
  4. Active tuberculosis or cystic fibrosis.
  5. Severe chronic respiratory disease including chronic obstructive pulmonary disease or pulmonary fibrosis requiring home oxygen > 5L/min.
  6. Use of extracorporeal membrane oxygenation (ECMO) during the current hospitalization.
  7. Pre-existing pulmonary hypertension.
  8. Severe pre-existing hepatic impairment (presence of cirrhosis, liver function tests (LFTs) ≥ 6x baseline, INR ≥ 2.0).
  9. Pre-existing Chronic Kidney Disease (CKD) stage IIIb or End Stage Renal Disease (ESRD) prior to onset of COVID-19 (stage I, II, and IIIa are acceptable)
  10. Irreversible coagulopathy (e.g., frequently occluded vascular access despite anticoagulation, precipitous platelet drops concurrent with end-organ damage suggesting consumptive process) or irreversible bleeding disorder (e.g., frequent bleeding from vascular access, endotracheal tubes, and foley).
  11. Pneumonia clearly attributable to a non-COVID-19 related process, including aspiration pneumonia or pneumonia that is exclusively bacterial, or originating from a diagnosed alternative virus (e.g., influenza).
  12. Patients who are not full code.
  13. Endotracheal intubation duration ≤ 24 hours.
  14. Moribund-expected survival < 24 hours.
  15. Severe metabolic disturbances on presentation (e.g., ketoacidosis, pH < 7.3)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04493242


Locations
Layout table for location information
United States, Alabama
Helen Keller Hospital
Sheffield, Alabama, United States, 35660
United States, California
St. Joseph Heritage Healthcare
Anaheim, California, United States, 92805
United States, Pennsylvania
Donald Guthrie Foundation/ Robert Packer Hospital
Sayre, Pennsylvania, United States, 18840
United States, Texas
Memorial Hermann Memorial City Medical Center
Houston, Texas, United States, 77024
Covenant Health System
Lubbock, Texas, United States, 79410
PRX Research
Mesquite, Texas, United States, 75149
Sponsors and Collaborators
Direct Biologics, LLC
Investigators
Layout table for investigator information
Study Director: Amy Lightner, MD Direct Biologics, LLC
Additional Information:
Layout table for additonal information
Responsible Party: Direct Biologics, LLC
ClinicalTrials.gov Identifier: NCT04493242    
Other Study ID Numbers: DB-EF-PHASEII-001
First Posted: July 30, 2020    Key Record Dates
Last Update Posted: January 19, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Direct Biologics, LLC:
COVID-19
ARDS
Extracellular Vesicles
Exosome
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases